A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-04022018-152619


Type of Document Dissertation
Author Buenrostro, Denise
URN etd-04022018-152619
Title The role of TGF-B responsive myeloid cell in tumor induced bone disease
Degree PhD
Department Cancer Biology
Advisory Committee
Advisor Name Title
Harold L. Moses Committee Chair
Albert B. Reynolds Committee Member
Julie A. Sterling Committee Member
Linda J. Sealy Committee Member
Scott A. Guelcher Committee Member
Keywords
  • Myeloid cells
  • tumor-induced bone disease
  • 1D11
  • TGF-B
Date of Defense 2018-03-23
Availability unrestricted
Abstract
The bone-tumor microenvironment is recognized as a dynamic place where critical cell interactions occur and play an important role in altering tumorigenesis. While many studies have investigated the effects of cellular cross-talk within distinct tumor microenvironments, these interactions have yet to be fully examined in bone. It is well-established that breast cancer metastasizes to bone, resulting in the development of tumor-induced bone disease (TIBD), a multi-facetted illness that is driven by complex cell interactions within the bone marrow. Our group has previously published that myeloid progenitor cells expand in the presence of tumors in bone, aligning with the notion that myeloid cells can act as tumor promotors. Several groups, including ours, have established that transforming growth factor β (TGF-β), an abundant growth factor in bone, can regulate both TIBD and myeloid expansion. TGF-β inhibitors have been shown to increase bone volume, decrease bone destruction, and reduce but not eliminate tumor. Therefore, we investigated the effect of TGF-β inhibition on myeloid expansion, tumor in bone and osteoclast-mediated bone loss, an overall analysis of TIBD. To address this, two different mouse models of breast cancer bone colonization were pre-treated with the TGF-β neutralizing antibody, 1D11, prior to tumor inoculation (athymic: MDA-MB-231, BALB/c: 4T1) and continuously treated until sacrifice.

Additionally, a genetically modified mouse model with a myeloid specific deletion of transforming growth factor beta receptor II (TGF-βRII) (TGF-βRIIMyeKO) was utilized in our studies. Early TGF-β inhibition affected expansion of distinct myeloid populations and shifted the cytokine profile of pro-tumorigenic factors in bone, 4T1 tumor cells, and bone-marrow derived macrophages and reduced overall TIBD.

Similar observations were seen in tumor-bearing TGF-βRIIMyeKO mice, where these mice contained fewer bone lesions and significantly less tumor burden in bone, suggesting that TGF-β inhibition regulates myeloid expansion leading to a significant reduction in TIBD. All of this together suggests that TIBD is a complex and multifaceted illness that involves several factors that include the bone and several cellular subsets of the microenvironment.

Files
  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  Buenrostro.pdf 3.94 Mb 00:18:14 00:09:23 00:08:12 00:04:06 00:00:21

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.